NZ610487A - Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins - Google Patents

Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins

Info

Publication number
NZ610487A
NZ610487A NZ610487A NZ61048711A NZ610487A NZ 610487 A NZ610487 A NZ 610487A NZ 610487 A NZ610487 A NZ 610487A NZ 61048711 A NZ61048711 A NZ 61048711A NZ 610487 A NZ610487 A NZ 610487A
Authority
NZ
New Zealand
Prior art keywords
cancer
human
treatment
fusion proteins
soluble
Prior art date
Application number
NZ610487A
Other languages
English (en)
Inventor
Harold Keer
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Priority to NZ703919A priority Critical patent/NZ703919A/en
Publication of NZ610487A publication Critical patent/NZ610487A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NZ610487A 2010-11-15 2011-11-14 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins NZ610487A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ703919A NZ703919A (en) 2010-11-15 2011-11-14 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41394010P 2010-11-15 2010-11-15
US42146210P 2010-12-09 2010-12-09
PCT/US2011/060661 WO2012068030A1 (en) 2010-11-15 2011-11-14 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins

Publications (1)

Publication Number Publication Date
NZ610487A true NZ610487A (en) 2015-03-27

Family

ID=44993965

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ610487A NZ610487A (en) 2010-11-15 2011-11-14 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
NZ703919A NZ703919A (en) 2010-11-15 2011-11-14 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
NZ703786A NZ703786A (en) 2010-11-15 2011-11-14 Fgfr1 extracellular domain combination therapies
NZ610538A NZ610538A (en) 2010-11-15 2011-11-14 Fgfr1 extracellular domain combination therapies

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ703919A NZ703919A (en) 2010-11-15 2011-11-14 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
NZ703786A NZ703786A (en) 2010-11-15 2011-11-14 Fgfr1 extracellular domain combination therapies
NZ610538A NZ610538A (en) 2010-11-15 2011-11-14 Fgfr1 extracellular domain combination therapies

Country Status (14)

Country Link
EP (2) EP2640377B1 (cg-RX-API-DMAC7.html)
JP (4) JP6178240B2 (cg-RX-API-DMAC7.html)
KR (3) KR101910779B1 (cg-RX-API-DMAC7.html)
CN (2) CN107050426A (cg-RX-API-DMAC7.html)
AU (2) AU2011329125B2 (cg-RX-API-DMAC7.html)
BR (2) BR112013012040A2 (cg-RX-API-DMAC7.html)
CA (2) CA2817537A1 (cg-RX-API-DMAC7.html)
EA (2) EA025828B1 (cg-RX-API-DMAC7.html)
IL (2) IL226248A0 (cg-RX-API-DMAC7.html)
MX (2) MX349293B (cg-RX-API-DMAC7.html)
NZ (4) NZ610487A (cg-RX-API-DMAC7.html)
SG (2) SG190248A1 (cg-RX-API-DMAC7.html)
WO (2) WO2012068032A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201303501B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
WO2013074492A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. Methods of treating cancer
CA2908391A1 (en) * 2013-05-01 2014-11-06 Five Prime Therapeutics, Inc. Methods of treating cancer
WO2014190147A2 (en) * 2013-05-23 2014-11-27 Five Prime Therapeutics, Inc. Methods of treating cancer
EA034376B1 (ru) * 2013-07-05 2020-01-31 Интегра Медикал Инк. Композиции для оздоровления полости рта
WO2015066452A2 (en) * 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating pediatric cancers
MX394623B (es) 2016-02-04 2025-03-24 Ads Therapeutics Llc Tecnología de sinergismo anticuerpo-fármaco para el tratamiento de enfermedades.

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5288855A (en) 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
WO1991000916A2 (en) 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ATE243253T1 (de) 1990-07-06 2003-07-15 Rhone Poulenc Rorer Internat H Rezeptoren der wachstumsfaktoren aus fibroblasten
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5229501A (en) 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
CN104231078A (zh) 1997-04-07 2014-12-24 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
WO2000046380A2 (en) 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
PT1292335E (pt) 2000-06-23 2007-08-13 Bayer Schering Pharma Ag Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii)
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
KR100976076B1 (ko) 2003-05-22 2010-08-17 아보트 러보러터리즈 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
WO2006081430A2 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
ZA200903134B (en) * 2006-11-28 2010-08-25 Centelion Modified soluble FGF receptor FC fusions with improved biological activity
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗-vegf抗體
PT2498799T (pt) * 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2

Also Published As

Publication number Publication date
ZA201303501B (en) 2016-07-27
MX2013005387A (es) 2013-10-17
IL226248A0 (en) 2013-07-31
AU2011329127B2 (en) 2015-09-03
KR20180053420A (ko) 2018-05-21
MX349293B (es) 2017-07-21
AU2011329127A1 (en) 2013-05-02
BR112013012040A2 (pt) 2016-08-16
BR112013012041A2 (pt) 2016-11-08
IL226252B (en) 2018-05-31
EP2640406A1 (en) 2013-09-25
SG190248A1 (en) 2013-06-28
KR101910779B1 (ko) 2018-10-22
NZ703919A (en) 2016-04-29
EA025828B1 (ru) 2017-02-28
JP2017019843A (ja) 2017-01-26
JP6178240B2 (ja) 2017-08-09
JP2014500873A (ja) 2014-01-16
NZ703786A (en) 2016-08-26
WO2012068032A1 (en) 2012-05-24
WO2012068030A1 (en) 2012-05-24
JP2016196475A (ja) 2016-11-24
CN107050426A (zh) 2017-08-18
CA2817583A1 (en) 2012-05-24
EA201390716A1 (ru) 2014-02-28
KR20130114676A (ko) 2013-10-18
NZ610538A (en) 2015-02-27
IL226252A0 (en) 2013-07-31
AU2011329125A1 (en) 2013-05-02
EP2640377A1 (en) 2013-09-25
ZA201303573B (en) 2016-07-27
CN103347514A (zh) 2013-10-09
JP5945277B2 (ja) 2016-07-05
MX2013005388A (es) 2013-11-04
EA201390722A1 (ru) 2013-11-29
CA2817537A1 (en) 2012-05-24
CN103347514B (zh) 2017-02-08
KR20130124513A (ko) 2013-11-14
EP2640377B1 (en) 2018-12-26
AU2011329125B2 (en) 2015-07-30
SG190788A1 (en) 2013-07-31
JP2013543870A (ja) 2013-12-09

Similar Documents

Publication Publication Date Title
AU2024264558B2 (en) Bicyclic peptide ligands specific for Nectin-4
NZ703919A (en) Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
NZ703153A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
SG170730A1 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
PH12013500542A1 (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
RU2014102924A (ru) Композиция для контролируемой стимуляции яичников
Machado-Silva et al. Therapeutic uses for Angiotensin-(1-7)
JP2019006785A (ja) Vegf阻害剤とイリノテカンとを含有する抗腫瘍性の組み合わせ
KR101629913B1 (ko) 중피종 치료용 접합체
JP2014500873A5 (cg-RX-API-DMAC7.html)
JOP20190019B1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
HK1188958A (en) Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
RU2023102211A (ru) Схемы дозирования иммуноконъюгата anti-folr1
HK40117195A (en) Bicyclic peptide ligands specific for nectin-4
HK40121640A (en) Bicyclic peptide ligands specific for nectin-4
MX2025001881A (es) Terapia que comprende anticuerpos anti cumulo de diferenciacion 19 (cd19) y moduladores del homologo 2 del potenciador de la proteina zeste (ezh2)
NZ775405B2 (en) Humanized antibodies against c-kit
NZ780958A (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
HK40050151A (en) Bicyclic peptide ligands specific for nectin-4
HK40050151B (en) Bicyclic peptide ligands specific for nectin-4
NZ761634A (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
NZ780958B2 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
UA95797C2 (ru) Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста
CN102258781A (zh) 一种治疗肝癌的靶向药物组合物

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2016 BY COMPUTER PACKAGES INC

Effective date: 20151020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2017 BY COMPUTER PACKAGES INC

Effective date: 20161018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2018 BY SORAIA DA SILVA

Effective date: 20171113

LAPS Patent lapsed